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Abstract
Background: The treatment of the primary tumor in advanced metastatic colorectal cancer
(CRC) is still a matter of discussion. Little attention has thus far been paid to the endoscopically
observable changes of the primary in non-curatively resectable stage IV disease.
Methods: 20 patients [14 men, 6 women, median age 67 (39–82) years] were observed after initial
diagnosis of non-curatively resectable metastasized symptomatic (83%) or asymptomatic (17%)
CRC, from June 2002 to April 2009. If necessary, endoscopic tumor debulking was performed. 5-
FU based chemotherapy was given immediately thereafter. In 10 patients, chemotherapy was
combined with antibody therapy.
Results: Response of the primary was observed in all patients. Local symptoms were treated
endoscopically whenever necessary (obstruction or bleeding), and further improved after
chemotherapy was started: Four patients showed initial complete endoscopic disappearance of the
primary. In an additional 6 patients, only adenomatous tissue was histologically detected. In both
these groups, two patients revealed local tumor relapse after interruption of therapy. Local tumor
regression or stable disease was achieved in the remaining 10 patients. 15 patients died during the
observation time. In 13 cases, death was related to metastatic disease progression. The mean
overall survival time was 19.6 (3–71) months. No complications due to the primary were observed.
Conclusion: This study shows that modern anti-cancer drugs combined with endoscopic therapy
are an effective and safe treatment of the symptomatic primary and ameliorate local complaints
without the need for surgical intervention in advanced UICC stage IV CRC.
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Background
Metastasizing colorectal cancer (CRC) is one of the lead-
ing causes of tumor-related death [1]. At the time of diag-
nosis, about 20% of the tumors have synchronous non-
resectable liver metastases [2,3]. In these patients, the aim
of treatment is to prolong survival and to maintain an
acceptable quality of life. Modern chemotherapy may
serve this purpose [2,4]. Depending on the regimen used,
response rates vary between 20–70% [5,6]. Most phase III
trials using combination therapy have reported a response
rate on the order of 40% [7]. In 20–30%, stability of the
metastases can be achieved [8,9]. Mean survival time in
patients with advanced stage CRC varies between 12–21
months after diagnosis [10].
With the development of modern chemotherapy and
endoscopic techniques, new therapeutical options for the
treatment of advanced metastasized CRC have emerged.
The 5-FU-leucovorin-based regimen combined with oxali-
platin or irinotecan was approved for the first-line treat-
ment of advanced CRC and has become the treatment
standard [11]. Combination with antibody therapy, such
as the anti-VEGF-antibody bevacizumab [8] or the anti-
EGFR-antibody cetuximab have become further options
[12].
However, surgical treatment of the primary tumor in non-
curatively resectable stage IV disease is still a matter of dis-
cussion [13-15]. In the past, investigators have recom-
mended elective resection of the primary tumor to prevent
the need for urgent surgical procedures arising from local
complications [16]. More recently, some authors have
suggested elective resection of asymptomatic colorectal
cancers at least in a subset of patients with less advanced
stage IV disease [17,18]. Others have suggested deferring
the resection of minimally symptomatic CRC, as in most
of these patients death is related to systemic disease pro-
gression rather than complications related to the primary
lesion [2,19]. In the setting of incurable stage IV CRC, in
which colonic resection has further been associated with a
high mortality rate [19,20] no survival advantage is
gained by resection of an asymptomatic primary lesion
[21].
As metastatic disease progression determines the outcome
of these patients, efforts have been concentrated on the
surveillance of tumor-related metastasis, typically meas-
ured by imaging techniques at scheduled intervals [22-
24]. In case of non-resected asymptomatic CRC, surveil-
lance does generally not include colonoscopies at tight
intervals. Local inspection of the primary may be repeated
to select patients for operation from a primarily non-oper-
ative setting.
Encouraging preliminary studies [14,25,26] prompted us
to observe the local tumor behaviour in patients with
non-curatively resectable stage IV CRC during chemother-
apy treatment. We are aware that modern treatment of
these patients is based on individual treatment concepts
which need to be re-evaluated during the course of ther-
apy. Sometimes, resection of metastasis is possible so that
palliative chemotherapy becomes a later therapy option.
We here report on the local tumor behaviour, the time-to-
progression of the primary and the overall survival of 20
patients treated with modern pharmacotherapy with or
without endoscopic tumor debulking.
Patients
For the current study, all the 23 patients with unoperated
primary tumors and unresectable metastatic UICC stage
IV CRC seen in the Department of Gastroenterology, Uni-
versity Clinic Goettingen, between June 2002 and June
2008 were considered for inclusion. Patients had to be
able and willing to receive chemotherapy with – if neces-
sary – local tumor debulking. Patients with significant car-
diovascular disease or inadequate hematologic
parameters were excluded. Of the 23 patients, the follow-
ing three patients were not included in this study: One 83
year old female patient declined chemotherapeutic treat-
ment, an 80 year old female patient had initially been
operated and now presented with local recurrence, and
one 62 year old male patient died of an infection after
replacement of the tricuspid valve shortly after the cancer
was diagnosed. The remaining 20 patients form our study
collective and were observed until April 2009. Table 1
summarises the patients' characteristics.
Data collection and publication of the data was approved
by the local ethics committee. All patients were chemo-
therapy naïve at the beginning of this study and above 18
years of age. They had adequate hematologic parameters
(absolute neutrophil count ≥ 1–5 × 103/μl and platelets ≥
100 × 103/μl), creatinine and total bilirubin < 2.25 times
the upper limit of normal and absence of active infection.
Methods
Tumor staging was undertaken before therapy and every
three to four months after the beginning of treatment.
After the initial staging and a possible initial tumor
debulking, the patients underwent chemotherapy treat-
ment.
Endoscopic tumor debulking of the primary tumor was
performed if the tumor mass resulted in a luminal
obstruction of about 80% or above as detected endoscop-
ically during staging, or if bleeding or obstruction symp-
toms were reported. The endoscopic treatment was done
either by using a standard polypectomy snare technique
alone or in combination with argon plasma coagulation.BMC Cancer 2009, 9:218 http://www.biomedcentral.com/1471-2407/9/218
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If the metastasis was considered operable during ongoing
treatment, operation of both the metastasis and of the pri-
mary was offered.
Staging included the measurement of the tumor marker
CEA (carcino embryonic antigen) and the imaging of the
metastasis (CT scan or ultrasound) and, if considered nec-
essary, the inspection of the local tumor by sigmoidos-
copy or colonoscopy. Endoscopy was initially performed
every three to four months in non-symptomatic patients.
In symptomatic patients, endoscopic tumor debulking
was performed at, on average, two sessions (range 1–5) in
the first two months.
Since endoscopic examinations can be associated with
complications, we comment that there is a question as to
how often they should be performed. For the patients in
this study, the high degree of luminal obstruction initially
suggested regular examination and where appropriate,
debulking.
Complete response of the primary was defined as macroscop-
ically intact mucosa and histologically confirmed absence
of malignant cells in the biopsy.
Partial response of the primary was defined as macroscopic
tumor regression with histologically confirmed tumor
cells.
Endoscopic regression of the primary has not previously
been defined in the literature. The inspection of the gut
lumen was done by experienced endoscopists (TA, JGS,
HS, GR), and included the description of bowel motility
and the possibility of passage of the tumor with a colono-
scope. Depending on the macroscopic appearance, the
decision had to be taken whether endoscopic intervention
was needed. Complete luminal occlusion – no passage
possible with the thinnest endoscope (4 mm) – was rated
100%. If the tumor could just be passed with the colono-
scope (14 mm), luminal occlusion was considered to be
85%. We are of course aware this is a rather subjective
method.
Statistical considerations
The primary objective of this study was to evaluate the
response of the primary tumor to up-to-date anti-cancer
therapy. Time-to-progression of the primary and overall
survival were estimated by the Kaplan-Meier method.
Data are expressed as mean, median (range) and per cent.
Calculations were performed with SPSS™ (version 13) and
SigmaPlot™ (version 10).
Results
Patients
Twenty patients [14 men, 6 women, median age 67 (39–
82) years] with non-resectable UICC stage IV CRC (14
colon, 6 rectum) at diagnosis were included from June
2002 to June 2008 and documented until April 2009. The
obtained data were retrospectively analysed. Eastern
Cooperative Oncology Group Performance Status
(ECOG) before initiation of the therapy was 0 or 1 in one
and twelve patients, respectively (65%) and ≥ 2 in seven
patients (35%). The majority of the patients (12/20) had
more than one site of synchronous metastases. Liver
metastases were predominant and present in 17 patients
(85%). Other sites of metastasis included, in decreasing
frequency of occurrence, lung, lymph nodes and perito-
neum as well as bone (Table 1).
Treatment Administration
In 17 of the 20 patients (85%), endoscopic tumor debulk-
ing was performed prior to and, if necessary, in parallel
with chemotherapy. In 3 patients, stool passage was re-
established [27]. In another 4 patients, repeated bleeding
was stopped.
Table 1: Tumor characteristics at baseline in patients with 
advanced stage IV CRC.
No. of patients n = 20 %
Age (Years) 67 (39–82)
Median (range)
Sex
Male 14 70%
Female 6 30%
Tumor origin
Colon 14 70%
Rectum 6 30%
Performance status (ECOG)
01 5 %
11 2 6 0 %
25 2 5 %
32 1 0 %
40 0 %
Sites of synchrone metastases
Liver 17 85%
Lung 11 55%
Lymph nodes 5 25%
Peritoneal 2 10%
Bone 1 5%
Number of metastatic sites
18 4 0 %
26 3 0 %
≥36 3 0 %BMC Cancer 2009, 9:218 http://www.biomedcentral.com/1471-2407/9/218
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The patients were then subjected to a modern chemother-
apy regimen either starting with FOLFOX (folinic acid, 5-
fluorouracil (FU), oxaliplatin) in 15 patients or with
FOLFIRI (folinic acid, 5-FU, irinotecan) in three patients.
One patient started with Xeliri and another patient (82
years) with a bad performance status (ECOG 3) initially
received the Ardalan protocol (folinic acid, 5-FU). In 50%
of the 20 cases, chemotherapy was combined with anti-
body therapy. Nine of these patients received bevacizu-
mab (Avastin), one patient received cetuximab (Erbitux).
In 13 patients, chemotherapy was started within the first
week after tumor diagnosis. In the remaining patients (7/
20), chemotherapy was started within two weeks after
diagnosis.
Chemotherapy was given over, on average, 13 months
(SD ± 11) with a mean observation time of 14 months
(Figure 1).
Safety and toxicity
In most of the patients, the treatment was well-tolerated.
Treatment-induced grade 3 and 4 toxicities which resulted
in a reduction of treatment or a change of the treatment
regimen included leukopenia (3 patients), anemia (1
patient), infection (2 patients), diarrhea (2 patients),
polyneuropathy (2 patients), and hand-foot syndrome (1
patient). Thrombembolic complications were suspected
in two patients. In one of these patients bowel perforation
occurred, making emergency operation necessary (Pat.
10). At the time, the patient had received a combination
therapy including bevacizumab. There was no clear rela-
tion with endoscopic treatment, as the perforation was
noted 5 weeks after the last colonoscopy. In all patients
receiving bevacizumab, no bleeding complication
occurred. More than one adverse event was found in 3
patients. 11 patients (55%) did not show treatment-rele-
vant side effects.
However, nine patients received less than 6 months of
chemotherapy as after an initial general improvement,
clinical condition declined due to general disease progres-
sion.
Observation of clinical symptoms
Initial symptoms were reported in 95% of the evaluable
patients (17/18). Local symptoms of the primary were
reported in 83% (15/18). Initial symptoms of the primary
tumor included bleeding in 44% (8/18) of the patients,
pain in 44% (8/18), and irregular stools in 50% (9/18).
Accompanying symptoms at presentation were reported
in 78% (14/18) of these patients. They included weight
loss (56%, 10/18), night sweat (39%, 7/18), and fatigue
(28%, 5/18).
At the first follow-up staging visit after 3 to 4 months of
therapy, both, local as well as general symptoms had
improved. As for local symptoms, bleeding was only
reported in 5% (1/18) of the patients. This patient had
received acetyl salicylic acid. Pain was recorded in 11% (2/
18), and irregular stools in 11% (2/18) of the patients.
Accompanying symptoms at follow-up were mainly
reduced to fatigue (28%, 5/18), which also might be a
side effect of chemotherapy and/or accompanying ane-
mia. Further weight loss was only reported in one patient
(5%, 1/18) and night sweat in another patient (5%, 1/18).
Local behaviour of the primary
In all patients, stable disease or regression of the primary
tumor during therapy was observed (Table 2, Figure 2 and
3). This response was an early event, and was already seen
at the first endoscopic inspection, in some cases as early as
after one month of therapy. None of the patients had to
be operated because of complications due to uncontrolled
growth of the primary tumor.
Complete initial luminal response of the primary CRC,
with no malign tumor material at biopsy, was found in
10/20 (50%) of the cases. In four patients, the luminal
side of the intestine was completely intact with no adeno-
matous tissue visible during endoscopy. Later-on, two of
these patients showed local tumor relapse after cessation
of systemic therapy: One patient 53 months after therapy
interruption. This patient had initially been considered as
cured (Pat. 3). The other patient (Pat. 20) showed luminal
tumor recurrence 2.5 months after therapy interruption
due to pneumonia with sepsis.
In the other six patients, only adenomatous tissue was
found histologically. Examples are given in Figure 2C and
2F, and Figure 3C. After interruption of the therapy at the
patients' request for a break, two of these patients showed
local tumor relapse as well (Pat. 6 and 8).
The 10 patients with complete initial luminal response are
summarized into two groups. Group I: Complete
response of the primary with I a, normal mucosa; and I b,
adenomatous tissue (table 2). The patients who relapsed
after therapy interruption are in group II.
In the remaining 10 patients (50%), partial luminal
response or stable disease of the primary was observed
(table 2). In these cases, the primary CRC remained mac-
roscopically apparent. These patients are summarized as
group III.
Tumor debulking was performed in patients with initial
symptoms due to the primary. As, at that time, we could
not predict what the effect of chemotherapy would be, inBMC Cancer 2009, 9:218 http://www.biomedcentral.com/1471-2407/9/218
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this group (group III) "prophylactic"endoscopic treat-
ment was repeated to prevent possible recurring luminal
obstruction, especially in those patients who were not
able to complete chemotherapy cycles or in whom the
dosage had to be reduced. This was the case in six patients.
In one of the patients, the primary carcinoma as well as
the tumor in the lung was operated after local tumor
regression (Pat. 14).
Overall survival and time-to-progression of the primary
At the cut-off date, the observation time of the study was
6 years and 9 months. Median follow-up time was 14
months (range 3–71 months), as 15 patients had died
during the observation period. In none of these patients
was death related to local complications or growth of the
primary.
In group I and II, five out of 10 patients (50%) died of
metastatic disease progression (Table 2). Mean overall
survival time (OS) for these groups taken together was 25
months (median 22.5, range 6 to 71 months).
In group III, which includes patients with macroscopic
regression of the primary with histologically confirmed
tumor cells at the end of the observation time, eight out of
ten patients (80%) died of metastatic disease progression.
Mean OS in this group was 14 months (median 11, range
3 to 31 months).
OS over the whole patient collective was, on average, 19.6
months (median 14, range 3 to 71 months) (Figure 4a). It
was significantly improved when 100% of the calculated
chemotherapy dosage could be given and chemotherapy
cycles were completed (Table 2). Time-to-progression
(TTP) of the primary was in the mean 13.6 months
(median 10, range 3–67 months, Figure 4b). The sub-
group-analysis of group II showed a TTP of in the mean 29
months (median 20.5, range 8 to 67 months).
In fact, under ongoing chemotherapy with completed
chemotherapy cycles, progress was observed only for the
metastases and not for the primary. Additional secondary
metastasis to the lung, the peritoneum or the bone mar-
row under ongoing chemotherapy occurred in eight of the
20 patients (40%).
Discussion
For most patients with CRC, surgical resection with or
without chemo(-radio)therapy is the standard treatment
approach. The treatment of surgically non-curable metas-
tasis of colorectal cancer is palliative chemotherapy
[28,29].
Taking into account that in many cases bleeding of the
tumor or obstructive disturbances can now be treated
endoscopically [25,27,30], the indication for surgery of
the primary tumor in patients with unresectable meta-
static CRC appears more controversial [13,21,31]. The fact
that after primary-directed-surgery in stage IV disease a
significant proportion of patients do not get palliative
chemotherapy; e.g. in the study of Temple et al. 40% of
the patients above 65 years of age did not receive chemo-
therapy after surgery of the primary tumor [32], argues
against initial surgery of the primary. Supporting this
argument, several retrospective studies have shown that
first-line chemotherapy is safe [21] and more effective
than it was before 2002 [31]. In addition, the rate of gas-
trointestinal complications related to the unresected pri-
mary is low and comparable to those observed in resected
patients [14,21]. When surgical resection of the primary
was compared to conservative treatment in the setting of
incurable stage IV disease, no survival advantage was
Time of chemotherapy administration (black bars), relative to  individual observation time Figure 1
Time of chemotherapy administration (black bars), 
relative to individual observation time. The grey bars 
mark the time without chemotherapy. Group numbers refer 
to the response of the primary, described in Table 2.BMC Cancer 2009, 9:218 http://www.biomedcentral.com/1471-2407/9/218
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Table 2: Individual local tumor response.
Macroscopic tumor response Patient Initial tumor size
(% tumor of intestinal lumen)
after 3–4 months of 
therapy
best response
Complete luminal 
response of the 
primary
(group I)
Normal mucosa (Ia) Pat. 07 85% 30% 30%
Pat. 09 85% 0% 0%
death related to metastasis n = 1 0 alive
related to other causes n = 1
Adenomatous tissue (Ib) Pat. 05* 85% 70% 30%
Pat. 10* R: 85%/L: 50% R: 60%/L: R: 60%/L: OP
Pat. 12 85% 30% 5%
Pat. 15* 95% 20% 40%
85%
death related to metastasis n = 3 0 alive
related to other causes n = 1
Relapse after 
therapeutic break 
(group II)
Initially no tumor cells at 
biopsy
Pat. 03 80% 60% 0%
Pat. 06* 85% 30% 30%
Pat. 08* 100% 85% 55%
Pat. 20* 75% 25% 25%
death related to metastasis n = 1 3 alive
related to other causes n = 0
Partial macros-copic 
response of the 
primary
(group III)
Histologically confirmed 
tumor tissue
Pat. 01* 85% 85% 85%
Pat. 02* 90% 85% 70%
Pat. 04* 85% 80% 80%
Pat. 11* 85% 75% 75%
Pat. 13* 100% 85% 85%
Pat. 14 60% 40% OP
Pat. 16* 60% 30% 20%
Pat. 17* 100% 85% 85%
Pat. 18* 90% 85% 85%
Pat. 19* 80% 70% 65%
death related to metastasis n = 8 2 alive
related to other causes n = 0
* incomplete = reduced amount of therapy or therapeutic breakBMC Cancer 2009, 9:218 http://www.biomedcentral.com/1471-2407/9/218
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gained by the resection of an asymptomatic primary [21].
It is understood that most of these patients die of their sys-
temic disease before the development of a major compli-
cation related to an intact primary lesion [21,33].
Although the number of patients in our study is limited, it
represents a further attempt to show that chemotherapeu-
tics combined with interventional endoscopy avoid the
need for resection of the primary in unresectable stage IV
CRC, even when the primary is symptomatic (obstructive
or bleeding). From our study we are unable to comment
on the relative effectiveness of chemotherapy or endo-
scopic debulking in isolation. However, interventional
endoscopy might not be necessary in asymptomatic
patients under effective chemotherapy.
The survival rate of our patients is similar to that of other
studies in which the primary tumor had been surgically
resected and where subsequent chemotherapy was possi-
ble [10]. We are aware that the results of our study should
be considered as tentative and hopefully will encourage
future larger studies. In mono-centric studies, large num-
bers cannot be obtained for this indication.
Patients' characteristics in our study were comparable to
other studies performed in a patient collective with metas-
tasizing CRC as regards the location of the primary and
the site of metastasis [8,12]. However, they were distinct
for age and performance status at the beginning of the
study. The median age in our study was, at 67 years, older
than the 65 years reported in other studies. Two Patients
were above 80, six patients were between 70 and 80 years
old. Six of the ten patients with macroscopic tumor regres-
sion (group III) were older than 70, and could not receive
complete chemotherapy courses. These patients are also
those who might not receive chemotherapy after primary-
directed surgery [32]. Old age is a negative prognostic fac-
tor for general outcome, making preventive medical
check-ups inevitable. Early administration of 100% of the
calculated chemotherapy dose with completed chemo-
therapy cycles was associated with a significantly better
OS and TTP of the primary in advanced disease.
Endoscopic images of the behaviour of a rectum carcinoma (A-C) and of another case with a carcinoma at the ileocoecal valve  (D-F) before and during therapy Figure 2
Endoscopic images of the behaviour of a rectum carcinoma (A-C) and of another case with a carcinoma at the 
ileocoecal valve (D-F) before and during therapy. A and D) at diagnosis; B and E) after endoscopic tumor debulking and 
three months, C) after 6 months, and F) after 15 months of chemotherapy.
A B C
DEFBMC Cancer 2009, 9:218 http://www.biomedcentral.com/1471-2407/9/218
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Conclusion
In the present study, combined endoscopic and pharma-
cological therapy was found to be effective and safe not
only in asymptomatic, but also in symptomatic advanced
stage IV CRC.
Our treatment improved both the initial symptoms of all
patients and reduced or stabilized the size of the primary
tumor. We therefore confirm and further expand the data
by Chau et al., and others who reported rapid sympto-
matic response after neoadjuvant treatment in patients
with colorectal cancer [13,31,34]. The survival rate of our
patients is similar to that of other studies in which the pri-
mary tumor had been operated [10]. Furthermore, this
study shows that anti-cancer drugs combined with endo-
scopic therapy may achieve a local response in the major-
ity of the patients: The primary tumor seems to respond
more effectively to chemotherapy than its metastases.
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